|
| | ARANIDIPINE Basic information |
| Product Name: | ARANIDIPINE | | Synonyms: | ARANIDIPINE;2，6-Dimethyl-4-(2-nitrophenyl)-1，4-dihydro-3，5-pyridinedicarboxylic acid methyl 2-oxopropyl ester;MPC-1304;Sapresta;1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-(2-oxopropyl) ester;Asanidipine;3,5-Pyridinedicarboxylicacid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3-methyl 5-(2-oxopropyl)ester;3-Methyl 5-(2-oxopropyl) 2,6-diMethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | | CAS: | 86780-90-7 | | MF: | C19H20N2O7 | | MW: | 388.37 | | EINECS: | | | Product Categories: | | | Mol File: | 86780-90-7.mol |  |
| | ARANIDIPINE Chemical Properties |
| Melting point | 155° | | Boiling point | 530.0±50.0 °C(Predicted) | | density | 1.284±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO : 125 mg/mL (321.86 mM) | | pka | 2.56±0.70(Predicted) |
| Toxicity | LD50 in male, female mice, rats (mg/kg): 143, 193, 1982, 1459 orally; LD50 in male, female mice (mg/kg): 7.3, 9.1 i.p. (Nakano) |
| | ARANIDIPINE Usage And Synthesis |
| Description | Aranidipine was launched in Japan as an antihypertensive agent.
Its pharmacological effects are similar to other dihydropyridine derivatives, e.g.,
nefidipine, however, it is more potent and longer lasting. This is partially due to the
fact that its initial metabolite (ketone reduction) is just as effective as the parent
compound. Aranidipine exerts its activity by blocking Ca+2 entry during depolarization
via L-type voltagegated Ca channels. This causes decreased levels of intracellular
Ca which leads to enhanced relaxation of smooth and cardiac muscle. It is a
selective α2-adrenoreceptor antagonist which inhibits vasoconstrictive responses. As
a dihydropyridine derivative, it can be synthesized via a modified Hantsch synthesis.
While sold as a racemate, the (S)-enantiomer is 150 times more active than the (R)-
antipode. | | Originator | Maruko Seiyaku (Japan) | | Definition | ChEBI: Aranidipine is an organic molecular entity. | | Manufacturing Process | 100.0 mg of 50% sodium hydride was added to a mixture of 20.0 g of 2,2-
ethylenedioxypropanol and 100 ml of benzene, and 20.0 g of diketene was
added dropwise to the mixture while refluxing the mixture. After refluxing the
mixture for 2 h, the solvent was distilled off and the resulting residue was
distilled under reduced pressure to obtain 21.5 g (70% yield) of 2,2-
ethylenedioxypropyl acetoacetate as a colorless oil, boiling point of 90°C (6
mm Hg).
Ammonia gas was passed through a mixture of 19.0 g of 2,2-
ethylenedioxypropyl acetoacetate and 100 ml of methanol for 2.5 h under icecooling
while stirring. The solvent was then distilled off and the residue was
distilled under reduced pressure to obtain 16.0 g (84% yield) of 2,2-
ethylenedioxypropyl 3-aminocrotonate as a pale yellow oil, boiling point of
120°C (5 mm Hg).
A mixture of methyl 2'-nitrobenzylidene acetoacetate, 2,2-ethylenedioxypropyl
3-aminocrotonate and ethanol was refluxed for 10 h. The resulting reaction
solution was allowed to stand overnight, and the precipitated crystals were
collected by filtration and recrystallized from ethanol to obtain methyl 2,2-
ethylenedioxypropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate.
Methyl 2,2-ethylenedioxypropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate was refluxed in an ethanol solution
containing 10% hydrochloric acid for 6 h. The solvent was then distilled off
and the residue was crystallized from diethyl ether to give methyl 2-oxopropyl
2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate as
yellow prisms, melting point 155°C (recrystallized from a mixture of ethyl
acetate and hexane). | | Brand name | Bec/Sapresta | | Therapeutic Function | Antihypertensive |
| | ARANIDIPINE Preparation Products And Raw materials |
|
